Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Frederic Baron, MD PhD, Marian Stevens-Kroef, PhD, Giovanna Meloni, MD, Petra Muus, MD PhD, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD PhD, Xavier Thomas, MD PhD, Radovan Vrhovac, MD PhD, Giorgina Specchia, MD, Francois Lefrere, Sr., MD, Simona Sica, Marco Mancini, MD, Adriano Venditti, MD, Anne Hagemeijer, MD, Joop H. Jansen, PhD, Sergio Amadori, MD, Theo de Witte, MD, Roelof Willemze, MD PhD, Stefan Suciu, PhD

Blood (2016) 128 (22): 2847.

https://doi.org/10.1182/blood.V128.22.2847.2847

Published: 2016

Journal Articles

Prevention of Viral Infections after T Cell Depleted Allogeneic Stem Cell Transplantation By Infusion of Multi-Antigen Specific T Cell Products

Marthe C.J. Roex, MD, Peter Van Balen, MD, Lois Hageman, Esther Van Egmond, Sabrina A.J. Veld, Conny Hoogstraten, Ellis van Liempt, PhD, Lothar Germeroth, PhD, Hermann Einsele, MD, Constantijn J.M. Halkes, MD PhD, Inge Jedema, PhD, J.H. Frederik Falkenburg, MD PhD

Blood (2016) 128 (22): 1228.

https://doi.org/10.1182/blood.V128.22.1228.1228

Published: 2016

Journal Articles

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Blood (2016) 128 (22): 2288.

https://doi.org/10.1182/blood.V128.22.2288.2288

Published: 2016

Journal Articles

HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age

Blood (2016) 128 (22): 4691.

https://doi.org/10.1182/blood.V128.22.4691.4691

Published: 2016

Journal Articles

A Polyclonal Population of Piga Mutant CD52 and GPI Anchor Negative T Cells Can Give Early Immune Protection after Alemtuzumab-Based T Cell Depleted Allogeneic Stem Cell Transplantation

Floris C. Loeff, J.H. Frederik Falkenburg, MD PhD, Lois Hageman, Sabrina A.J. Veld, Marian van de Meent, Constantijn J.M. Halkes, MD PhD, Inge Jedema, PhD

Blood (2015) 126 (23): 3134.

https://doi.org/10.1182/blood.V126.23.3134.3134

Published: 2015

Journal Articles

Loss of Pigh Expression Frequently Results in a GPI-Negative Subclone Lacking CD52 Membrane Expression, Conferring Alemtuzumab Resistance to B Cell Acute Lymphoblastic Leukemia

Floris C. Loeff, Kevin Rijs, Willem H. Zoutman, Esther H.M. Egmond, Maarten H. Vermeer, MD PhD, J.H. Frederik Falkenburg, MD PhD, Constantijn J.M. Halkes, MD PhD, Inge Jedema, PhD

Blood (2015) 126 (23): 1435.

https://doi.org/10.1182/blood.V126.23.1435.1435

Published: 2015

Journal Articles

Tumor Associated Antigen Reactive Donor T Cells As Elementary Components of Streptamer Isolated Multi-Antigen Specific T Cells

Marthe C.J. Roex, MD, Ellis van Liempt, PhD, Lois Hageman, Lothar Germeroth, PhD, Constantijn J.M. Halkes, MD PhD, J.H. Frederik Falkenburg, MD PhD, Inge Jedema, PhD

Blood (2014) 124 (21): 313.

https://doi.org/10.1182/blood.V124.21.313.313

Published: 2014

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Leonie I Kroeze, Mariam G Aslanyan, Arno van Rooij, Theresia N Koorenhof-Scheele, Marion Massop, Thomas Carell, Jan B Boezeman, Jean-Pierre Marie, MD, Constantijn J.M. Halkes, MD, PhD, Theo M. de Witte, MD, Gerwin Huls, Stefan Suciu, PhD, Ron Wevers, Bert A. van der Reijden, Joop H. Jansen, PhD

Blood (2013) 122 (21): 1261.

https://doi.org/10.1182/blood.V122.21.1261.1261

Published: 2013

Journal Articles

Effectivity Of Complement-Dependent Cytotoxicity Induced By Therapeutic Antibodies In Acute Lymphoblastic Leukemia Is Dictated By Antigen Expression Levels and Curtailed By Membrane-Bound Complement Regulatory Proteins

Floris C Loeff, MSc, Esther H.M. van Egmond, Judith Olde Wolbers, J.H. Frederik Falkenburg, MD, PhD, Constantijn J.M. Halkes, MD, PhD, Inge Jedema, PhD

Blood (2013) 122 (21): 3909.

https://doi.org/10.1182/blood.V122.21.3909.3909

Published: 2013

Journal Articles

Graft Versus Leukemia Separates From Graft Versus Host Disease By Magnitude and Avidity Of The Allo-Reactive T Cell Response After Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion

Cornelis A.M. van Bergen, Simone A.P. Van Luxemburg-Heijs, Matthijs Eefting, MD, Maria W. Honders, Inge Jedema, PhD, Constantijn J.M. Halkes, MD, PhD, Marieke Griffioen, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2013) 122 (21): 2014.

https://doi.org/10.1182/blood.V122.21.2014.2014

Published: 2013

Journal Articles

Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival.

Peter A. Von Dem Borne, MD, PhD, Constantijn J.M. Halkes, MD, PhD, Erik W.A. Marijt, MD, PhD, Sabina Kersting, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, J.Hendrik Veelken, MD, PhD

Blood (2012) 120 (21): 3085.

https://doi.org/10.1182/blood.V120.21.3085.3085

Published: 2012

Journal Articles

T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status

Jessica C. Harskamp, MD, Pim L.J. van der Heiden, MD, Esther H.M. van Egmond, Sabrina A.J. Veld, Hans L. Vos, PhD, Constantijn J.M. Halkes, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Erik W.A. Marijt, MD, PhD

Blood (2010) 116 (21): 1321.

https://doi.org/10.1182/blood.V116.21.1321.1321

Published: 2010

Journal Articles

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Constantijn J.M. Halkes, MD, PhD, Inge Jedema, PhD, Judith Olde Wolbers, Esther M van Egmond, Peter A. Von Dem Borne, MD, PhD, Erik W.A.F. Marijt, MD, PhD, J.H.Frederik Falkenburg, MD, PhD

Blood (2010) 116 (21): 2330.

https://doi.org/10.1182/blood.V116.21.2330.2330

Published: 2010

NARROW

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials

Prevention of Viral Infections after T Cell Depleted Allogeneic Stem Cell Transplantation By Infusion of Multi-Antigen Specific T Cell Products

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age

A Polyclonal Population of Piga Mutant CD52 and GPI Anchor Negative T Cells Can Give Early Immune Protection after Alemtuzumab-Based T Cell Depleted Allogeneic Stem Cell Transplantation

Loss of Pigh Expression Frequently Results in a GPI-Negative Subclone Lacking CD52 Membrane Expression, Conferring Alemtuzumab Resistance to B Cell Acute Lymphoblastic Leukemia

Tumor Associated Antigen Reactive Donor T Cells As Elementary Components of Streptamer Isolated Multi-Antigen Specific T Cells

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Aberrant 5-Hydroxymethylcytosine Levels Correlate With Poor Overall Survival In Acute Myeloid Leukemia

Effectivity Of Complement-Dependent Cytotoxicity Induced By Therapeutic Antibodies In Acute Lymphoblastic Leukemia Is Dictated By Antigen Expression Levels and Curtailed By Membrane-Bound Complement Regulatory Proteins

Graft Versus Leukemia Separates From Graft Versus Host Disease By Magnitude and Avidity Of The Allo-Reactive T Cell Response After Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion

Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival.

T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only